Erasca, Inc.

Equities

ERAS

US29479A1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.89 ^USD	+0.53%		+5.59%	-11.27%

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Apr. 02	Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating	MT

Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 04:15 pm EDT

Erasca, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 125.04 million compared to USD 242.81 million a year ago. Basic loss per share from continuing operations was USD 0.83 compared to USD 1.99 a year ago.

Latest news about Erasca, Inc.

North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating	Apr. 02	MT
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Erasca, Inc. announced that it expects to receive $45 million in funding	Mar. 26	CI
Capital One Initiates Erasca at Overweight Rating With $8 Price Target	Mar. 11	MT
Erasca Enters Two Supply Deals With Novartis for Trametinib	Feb. 14	MT
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	Feb. 14	CI
North American Morning Briefing : Boeing Drags -2-	Jan. 08	DJ
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	Dec. 11	CI
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing	Dec. 07	MT
HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating	Nov. 28	MT
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026	Nov. 28	MT
Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway	Nov. 28	CI
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HC Wainwright Initiates Erasca at Buy Rating With $10 Price Target	23-10-11	MT
Erasca Shares Jump After CEO Stock Purchase Disclosed	23-10-10	MT
Erasca Insider Bought Shares Worth $2,026,000, According to a Recent SEC Filing	23-10-10	MT
Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors	23-08-29	MT
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell 3000E Index	23-06-23	CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell Microcap Index	23-06-23	CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell Microcap Value Index	23-06-23	CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell 3000E Value Index	23-06-23	CI
Erasca's Eras-801 for Treatment of Brain Tumors Gets FDA Orphan Drug Designation	23-06-22	DJ

Chart Erasca, Inc.

Duration

Period

More charts

Company Profile

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.89 USD

Average target price

7 USD

Spread / Average Target

+270.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ERASCA, INC.	-11.27%	286M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research